ReviewJournal of leukocyte biology2016
At The Bedside: Clinical review of chimeric antigen receptor (CAR) T cell therapy for B cell malignancies.
Review in Journal of leukocyte biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 45 citations in OpenAlex.
- Living Medicines Engineered to Fight: A Comprehensive Review on CAR T-Cell Therapy.International journal of hematology-oncology and stem cell research · 2025Review
- Prolonged Cytopenia with CAR-T Cell Therapy and Management Recommendations.Clinical hematology international · 2025Article
- Recent progress in chimeric antigen receptor therapy for acute myeloid leukemia.Annals of hematology · 2024Review
- Quantifying requirements for mitochondrial apoptosis in CAR T killing of cancer cells.Cell death & disease · 2023Article
- Flow Cytometric Identification of Hematopoietic and Leukemic Blast Cells for Tailored Clinical Follow-Up of Acute Myeloid Leukemia.International journal of molecular sciences · 2022Review
- Emerging CAR T Cell Strategies for the Treatment of AML.Cancers · 2022Review
- Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy.Nature reviews. Immunology · 2022Review
- Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia.Cancers · 2022Review
- CAR T cells: Building on the CD19 paradigm.European journal of immunology · 2021Review
- Functional bionanomaterials for cell surface engineering in cancer immunotherapy.APL bioengineering · 2021Review
- Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies.Circulation research · 2021Review
- The Current Status of Gene Therapy for the Treatment of Cancer.Biologics : targets & therapy · 2021Review
- CART Cell Toxicities: New Insight into Mechanisms and Management.Clinical hematology international · 2020Article
- [allo-CD19-CAR-T cells therapy followed with same-donor allo-HSCT to treat relapsed B-ALL: two cases report and literatures review].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2020Article
- Article
- The making and function of CAR cells.Immunology letters · 2019Review
- Superior lentiviral vectors designed for BSL-0 environment abolish vector mobilization.Gene therapy · 2018Article
- Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy.Gene therapy · 2018Article
- CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade.Nature medicine · 2018Article
- A novel antibody-TCR (AbTCR) platform combines Fab-based antigen recognition with gamma/delta-TCR signaling to facilitate T-cell cytotoxicity with low cytokine release.Cell discovery · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
T cells kill microbial-infected and malignant cells by detection of nonself antigens with the TCR. Tumor reactivity can be encoded genetically by introducing a chimeric antigen receptor (CAR) into T cells. CARs are composed of an antigen-binding domain and an intracellular T cell activation domain. Early human trials evaluating CD19-targeted CAR T cells for chronic lymphocytic leukemia (CLL) showed limited responses until CARs included a costimulation domain, and conditioning chemotherapy was given before T cell infusion. Clinical trials evaluating CD19-targeted CAR T cells for B cell acute lymphoblastic leukemia (B-ALL) are demonstrating response rates up to 90%. However, these clinical outcomes are associated with a cytokine release syndrome (CRS), which is caused by T cell activation and manifests as high-grade fever, hypotension, and other cardiovascular complications. It is currently managed conservatively but can be treated with cytokine-directed therapy or with high-dose steroids. Current efforts are dedicated to confirming the clinical efficacy and managing toxicities in multicenter Phase II trials. We present a thorough overview of the preclinical and clinical development of CAR T cell therapy that will highlight important areas for the basic researcher to investigate in the laboratory and contribute to this exciting field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.